PlumX Metrics
Embed PlumX Metrics

Multi-omic approach identifies hypoxic tumor-associated myeloid cells that drive immunobiology of high-risk pediatric ependymoma

iScience, ISSN: 2589-0042, Vol: 26, Issue: 9, Page: 107585
2023
  • 2
    Citations
  • 0
    Usage
  • 22
    Captures
  • 0
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

  • Citations
    2
    • Citation Indexes
      2
  • Captures
    22

Article Description

Ependymoma (EPN) is a devastating childhood brain tumor. Single-cell analyses have illustrated the cellular heterogeneity of EPN tumors, identifying multiple neoplastic cell states including a mesenchymal-differentiated subpopulation which characterizes the PFA1 subtype. Here, we characterize the EPN immune environment, in the context of both tumor subtypes and tumor cell subpopulations using single-cell sequencing (scRNAseq, n = 27), deconvolution of bulk tumor gene expression (n = 299), spatial proteomics (n = 54), and single-cell cytokine release assays (n = 12). We identify eight distinct myeloid-derived subpopulations from which a group of cells, termed hypoxia myeloid cells, demonstrate features of myeloid-derived suppressor cells, including IL6/STAT3 pathway activation and wound healing ontologies. In PFA tumors, hypoxia myeloid cells colocalize with mesenchymal-differentiated cells in necrotic and perivascular niches and secrete IL-8, which we hypothesize amplifies the EPN immunosuppressive microenvironment. This myeloid cell-driven immunosuppression will need to be targeted for immunotherapy to be effective in this difficult-to-cure childhood brain tumor.

Bibliographic Details

Griesinger, Andrea M; Riemondy, Kent; Eswaran, Nithyashri; Donson, Andrew M; Willard, Nicholas; Prince, Eric W; Paine, Simon M L; Bowes, Georgia; Rheaume, John; Chapman, Rebecca J; Ramage, Judith; Jackson, Andrew; Grundy, Richard G; Foreman, Nicholas K; Ritzmann, Timothy A

Elsevier BV

Multidisciplinary

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know